Zielgerichtete Therapien beim rezidivierten Endometriumkarzinom 2: Moderne Ansätze

[1]  Su-Chun Cheng,et al.  A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor–Positive Recurrent Endometrial Cancer , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Italiano,et al.  Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Tinker,et al.  Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study , 2022, Journal for ImmunoTherapy of Cancer.

[4]  J. Pijnenborg,et al.  Recurrent Endometrial Cancer: Local and Systemic Treatment Options , 2021, Cancers.

[5]  G. Fleming,et al.  721O Relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel improves progression-free survival in patients with recurrent platinum-resistant ovarian cancer: A 3-arm, randomized, open-label, phase II study , 2021, Annals of Oncology.

[6]  M. Stockler,et al.  Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial , 2021, Journal for ImmunoTherapy of Cancer.

[7]  U. Matulonis,et al.  Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Qi Wang,et al.  Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990-2019. , 2021, Gynecologic oncology.

[9]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[10]  D. Levine,et al.  Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. , 2021, Gynecologic oncology.

[11]  H. Mackay,et al.  HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes , 2020, Cancers.

[12]  Cyrus Chargari,et al.  ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma , 2020, International Journal of Gynecological Cancer.

[13]  D. Cella,et al.  Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  F. Marmé,et al.  LBA28 A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced/recurrent endometrial cancer (EC): NSGO-PALEO / ENGOT-EN3 trial , 2020, Annals of Oncology.

[15]  E. Schmidt,et al.  Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Tagliaferri,et al.  Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial. , 2019, Gynecologic oncology.

[17]  S. Cannistra,et al.  Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Stuckey,et al.  A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. , 2018, Gynecologic oncology.

[19]  Jacques Ferlay,et al.  International Patterns and Trends in Endometrial Cancer Incidence, 1978-2013. , 2018, Journal of the National Cancer Institute.

[20]  H. Mackay,et al.  Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. , 2017, Gynecologic oncology.

[21]  H. Rugo,et al.  Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  E. Darai,et al.  Endometrial cancer , 2016, The Lancet.

[23]  A. Talhouk,et al.  A clinically applicable molecular-based classification for endometrial cancers , 2015, British Journal of Cancer.

[24]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[25]  J. V. Bokhman.  Two pathogenetic types of endometrial carcinoma. , 1983, Gynecologic oncology.